Tripos - Bioinformatik zum Discount - 500 Beiträge pro Seite

[Intuition]

Tripos, ein amerikanisches Bioinformatikunternehmen, wird derzeit zu Discountpreisen gehandelt.
Allein die 2 Mio. Anteile an Arena ( ebenfalls US- - Bioinformatikcompany ) übersteigen die derzeitige
Marktkapitalisierung.
Übrigens arbeiten Lion und Tripos eng zusammen, nach Aussage von Lion sind beide Unternehmen
durchaus vergleichbar.
Was mich erstaunt: MK Tripos 93,4 Mio. ( Yahoo Finanace ) MK Lion ca. 2000 Mio.
Tripos und Lion halten angeblich auch wechselseitig Anteile, für Lion ist Tripos die strategische Us - Eintrittskarte.
Die Umsätze von Tripos legen in Amerika deutlich zu, hierzulande scheint sich keiner dafür zu interressieren.

[Mauidoc]

Laß doch mal ein paar Zahlen für dich sprechen!
Evtl. den Chart in diesen Thread stellen?
Tschau Mauidoc

[claudechabrol]

hab auch ne speckulative tripos position(eine empfehlung oder ähnliches und die verdoppelt sich,nebenbei war die reaktion auf der 38er richtungsweisend denke ich))

[Intuition]

@ Mauidoc
Details unter Tripos.com bzw. Yahoo Finance.
Ich will den Wert übrigens nicht pushen, nur aufmerksam machen.
Mich würde interessieren, wieviel Anteile Lion an Tripos bzw. umgekehrt hat.
2. Ist Tripos ein Übernahmekandidat für Lion ?

[stockrula]

[urizano]

Ich weiß nicht ob hier noch jemand was liest, aber folgendes möcht ich mir nicht vernkneifen:

Yippiiiiiiiiiiiiiiiih!!!!!!!!!

Tripos ist der lonely star in meinem Portfolio. Und ich weiss auch warum. Unter Wissenschaftlern haben die Tripos-Tools schon lange einen guten Ruf, viele Dinge sind Gemeinschaftsprojekte mit führenden Instituten, z.B. in Deutschland mit der GMD-SCAI.

Das bisherige Manko waren die lausigen Financials, weil offenbar zu wenige der Wald-und-Wiesen-Biotechs die Software ordern. Das scheint sich nun verbessert zu haben, sie machen endlich Gewinne, und nicht zu knapp.

Jetzt auf neuem All-time-high werden vielleicht auch Durchschnittsinvestoren auf die Aktie aufmerksam!?

[papermaker]

@all,

bin mir sicher , die Story fängt erst an !

http://finance.yahoo.com/q?s=TRPS&d=v1

[golfer!]

Hi,
leider habe ich den Wert erst kürzlich entdeckt – hm......

Unter http://www.nasdaq.com/asp/quotes_reports.asp?symbol=TRPS`&s… und http://www.nasdaq.com/asp/quotes_reports.asp?symbol=TRPS`&s… habe ich mal ein paar Zahlen gefunden anhand derer man die beiden Unternhmen mal vergleichen kann.

Was mir bei TRPS im Moment jeoch nicht gefällt, sind die sehr stark angestiegenen Shortpositionen (von ca. 15.000 auf ca. 115.000) http://www.nasdaq.com/asp/quotes_full.asp?kind=shortint&sym….
Wobei bei Leon befinden sich die Shortpositionen schon die ganze Zeit auf über 240.000.

Kennt Ihr noch andere Zahlen anhand derer man die Unternehmen vergleichen kann??

Schönen Sonntag noch
Grüße Golfer

[golfer!]

Hi,
leider habe ich den Wert erst kürzlich entdeckt – hm......

Unter http://www.nasdaq.com/asp/quotes_reports.asp?symbol=TRPS`&s… und http://www.nasdaq.com/asp/quotes_reports.asp?symbol=TRPS`&s… habe ich mal ein paar Zahlen gefunden anhand derer man die beiden Unternhmen mal vergleichen kann.

Was mir bei TRPS im Moment jeoch nicht gefällt, sind die sehr stark angestiegenen Shortpositionen (von ca. 15.000 auf ca. 115.000) http://www.nasdaq.com/asp/quotes_full.asp?kind=shortint&sym….
Wobei bei Leon befinden sich die Shortpositionen schon die ganze Zeit auf über 240.000.

Kennt Ihr noch andere Zahlen anhand derer man die Unternehmen vergleichen kann??

Schönen Sonntag noch
Grüße Golfer

[papermaker]

Das wurde auch mal Zeit , das die Aktie auch in Deutschl.
mehr beachtet wird.


http://clearstation.etrade.com/cgi-bin/details?Symbol=TRPS&R…

Am 07.Februar kommen die Zahlen , nehme an , das man
sich auch über einen Split äußert .
Aber das wißt Ihr wohl schon alles.

Nebenbei , ich halte die Konsolidierung für abgeschlossen.

MfG,

pp

[papermaker]

http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4688292&…


aus dem Yahoo-Board ,

pp

[papermaker]

http://biz.yahoo.com/cc/3/14113.html


pp

[papermaker]

Wednesday February 6, 4:44 pm Eastern Time
Press Release
SOURCE: Tripos, Inc.
Tripos Announces 2001 Record Revenue and Earnings
Company Reports Fifth Consecutive Profitable Quarter
Tripos Posts 69% Year-Over-Year Growth
ST. LOUIS, Feb. 6 /PRNewswire-FirstCall/ -- The leading provider of drug discovery chemistry, software and enterprise informatics, Tripos, Inc. (Nasdaq: TRPS - news), today announced record revenues and earnings for the full year ended December 31, 2001. The Company also announced its fifth consecutive profitable quarter.

Tripos posted record revenues of $16.6 million for the fourth quarter ended December 31, 2001, a $3.8 million (29%) increase over the same period last year. For the full year 2001, Tripos recorded $49.1 million in revenues compared to $29.0 million in 2000, an increase of 69%. Net income allocable to common shareholders for the fourth quarter of 2001 was $1.8 million or $0.24 per basic share and $0.20 per fully diluted share. This compares with a net income of $2.3 million, or $0.32 per basic and $0.26 per diluted share for the year-ago quarter. For the full year 2001, net income allocable to common shareholders was $5.4 million or $0.74 per basic and $0.62 per diluted share, respectively, compared to a net loss allocable to common shareholders of $2.5 million or a loss of $0.35 per basic and diluted share in 2000. The 2001 net income included a $1.6 million ($0.21 per basic and $0.16 per diluted share) after-tax gain on the sale of shares of Arena Pharmaceuticals, Inc. in the second quarter of 2001.

``The demand for our integrated suite of drug discovery products, services, and collaborations continues to build, driving our financial performance to record levels,`` stated Dr. John P. McAlister, President and Chief Executive Officer of Tripos. ``We ended 2001 with a strong complement of existing contracts, a pipeline of new business, and expanding revenue streams in all our business areas giving us confidence in our business outlook as we enter 2002.``

According to Dr. McAlister, Tripos` significant revenue and earnings gains for 2001 continue to validate Tripos` strategy to diversify its drug discovery chemical research and enterprise service offerings around the Company`s core informatics expertise and intellectual property. The growth extended over all areas of the company`s offerings.

Major Operational Highlights in 2001

The year just ended was an eventful one for Tripos. The Company made significant progress in adding to its intellectual property rights, attracted new long-term business contracts and established working partnerships with some of the world`s best-known pharmaceutical research companies:

The Company was awarded two new patents in novel predicative computational methodology and combinatorial library design technology, both of which helped strengthen Tripos` intellectual property leadership in its markets.
Tripos successfully completed a collaboration with Lipha S.A., a subsidiary of Merck KGaA, to identify and synthesize novel drug candidates against Lipha targets.
Tripos announced an agreement with Schering AG to build a global enhanced chemical information system that will integrate Schering`s compound research data and inventory data.
AstraZeneca signed a discovery software licensing agreement to deploy Tripos` SYBYL® suite of in silico drug discovery technologies worldwide to its researchers.
In addition, Tripos kicked off 2002 with three multi-million dollar, multi-year Pfizer agreements -- to provide global software licensing; to develop LITHIUM(TM), a new software platform; and, in a major strategic chemistry collaboration valued at up to $100 million, to collaborate with Pfizer to design, synthesize and purify high-quality, drug-like compounds to expand Pfizer`s compound collection over a four- year term.
Full Year 2002 Outlook

``As we previously announced on January 9, 2002,`` said Dr. McAlister, ``because of our strong business pipeline, and our on-going multi-million dollar contracts announced last year and over the past month, we anticipate continued strong financial performance for 2002.``

The Company has publicly stated that it expects revenues in a range of $60 to $65 million in the year ahead, a 22% to 33% year-over-year improvement. Tripos expects fully diluted earnings per share from operations to be in the range of $0.64 to $0.70, and anticipates that each of its business segments (chemistry research, consulting services and discovery software) will meet or exceed growth rates of 25% in 2002.

Web Cast Information

Tripos, Inc. will host a web cast to discuss its quarterly and year-end financial results, business highlights and outlook for 2002. The call will be broadcast live over the Internet, Thursday, February 7, 2002, at 10:00 a.m. EDT/9:00 a.m. CDT. To listen to the live web cast, or the replay, please go to http://www.tripos.com .

About Tripos, Inc.

Tripos ( www.tripos.com ) is a leading provider of discovery chemistry, integrated discovery software products, software consulting services, and discovery research services to the pharmaceutical, biotechnology, agrochemical, and other life sciences industries. The company combines information technology and scientific research to optimize and accelerate molecular research for the discovery of new products by customers. Tripos` products include diverse chemical libraries; collaborative and contract research for the discovery, synthesis, characterization and optimization of new chemical compounds that are active in biological systems; proprietary discovery software tools to manage, analyze and share biological and chemical information; and systems integration and other software consulting services.

This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as ``expects,`` ``anticipates,`` ``projects,`` ``estimates,`` ``intends,`` ``plans,`` ``believes,`` variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Tripos has identified certain factors that could cause actual results to differ materially from the forward-looking statements in its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its Current Report on Form 8-K. Tripos undertakes no obligation to update any forward-looking statements contained herein.


Tripos, Inc.

pp

[papermaker]

Wednesday February 6, 5:02 pm Eastern Time
Tripos 4th qtr profit falls, sees `02 revs rising
ST. LOUIS, Feb 6 (Reuters) - Tripos Inc. (NasdaqNM:TRPS - news), which provides research technology to drug companies, posted a slightly lowerr fourth-quarter profit on Wednesday but said it sees 2002 revenue rising based on growing demand for its services.

St. Louis-based Tripos reported net income of $1.8 million, or 24 cents per share, compared with net income of $2.3 million, or 26 cents per share, in the year-earlier period.

Revenue in the quarter was $16.6 million, compared with $12.8 million in the year-ago period.

For 2002, the company said it expects to report revenue of $60 million to $65 million, up from $49.1 million in 2001, with pro forma operating earnings per share of 64 cents to 70 cents.

Shares in Tripos closed up 1.2 percent at $30.05 on Nasdaq. Their 52-week high is $34.49 and their 52-week low is $7.05.



pp

[papermaker]

LION Liquidates Its Holding in Tripos in Block Trade

ST. LOUIS, Feb. 7 /PRNewswire-FirstCall/ -- Tripos, Inc. (Nasdaq: TRPS), a leading provider of drug discovery chemistry, software and services, announced today that LION bioscience AG (Nasdaq: LEON, Neuer Markt: LIO, WKN 504 350), sold its entire holding of 812,182 shares of Tripos common stock in a block trade transaction handled by UBS Warburg.

Commenting on the LION transaction, Dr. John P. McAlister, President and Chief Executive Officer of Tripos, stated, "LION, which invested approximately $9 million in our company just two years ago, had achieved a substantial return on its investment and decided to liquidate this asset and deploy the proceeds in other parts of its business. We continue to work closely with LION on our collaboration with Bayer AG to create an integrated cheminformatics technology platform to speed Bayer`s identification of lead candidates for its drug and agricultural chemical programs. Our working relationship is not affected by this transaction."

Jim Rubin, Chief Financial Officer of Tripos, commented further that, "Due to this transaction, the public float of Tripos has increased from approximately 7.6 million shares to approximately 8.4 million shares in an orderly market transaction. Any uncertainty in the market regarding LION`s possible sale of these shares has now been removed."

As a result of this transaction, LION has liquidated its entire investment in Tripos and its rights under an investor rights agreement, including the right to designate a director, have terminated. About Tripos, Inc.

Tripos ( www.tripos.com ) is a leading provider of discovery chemistry, integrated discovery software products, software consulting services, and discovery research services to the pharmaceutical, biotechnology, agrochemical, and other life sciences industries. The company combines information technology and scientific research to optimize and accelerate molecular research for the discovery of new products by customers. Tripos` products include diverse chemical libraries; collaborative and contract research for the discovery, synthesis, characterization and optimization of new chemical compounds that are active in biological systems; proprietary discovery software tools to manage, analyze and share biological and chemical information; and systems integration and other software consulting services.

This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as "expects," "anticipates," "projects," "estimates," "intends," "plans," "believes," variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Tripos has identified certain factors that could cause actual results to differ materially from the forward-looking statements in its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its Current Report on Form 8-K. Tripos undertakes no obligation to update any forward-looking statements contained herein.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X86867776



/CONTACT: Melissa Jacobs, Director, Marketing Communications of Tripos, Inc., [phone], or [phone], or William G. Murphy, Managing Partner, Investor Relations of Figel Murphy Public Relations, [phone], for Tripos, Inc./

Mit einem Kursverlust von rund 10,5 % ( 9% & 1,5%) hat
Tripos das gut weggesteckt.
Auf jedenfall jetzt Kaufkurse , ab Montag geht es wieder
nach oben .

pp

Ps.: Tripos erhöht seine Mitarbeiterzahl um 25 %

[papermaker]

Meine Meinung :

Auch durch diese Transaktion wird LION bioscience AG

nicht profitabel werden .

pp

Bin ja mal gespannt wie lange ich hier noch den Alleinunterhalter spielen muß .
Bei dem Potienzal von Tripos ?

[papermaker]

Strong buy :


http://earnings.nasdaq.com/earnings/analyst_summary.asp?symb…" target="_blank" rel="nofollow ugc noopener">
http://earnings.nasdaq.com/earnings/analyst_summary.asp?symb…


pp

[analle]

@papermaker,


habe tripos seit anfang Januar02 auf meiner Watchliste, seit dem enorm gestiegen und kommen jetzt wieder runter, warte auf einen guten Einstieg.

Good luck.

[papermaker]

@analle ,

wie ich gestern schon sagte , es geht nach oben ,
nächster stop 35-40 $ , bei neuen Absclüssen ...???

MfG,

pp

[papermaker]

pp

[papermaker]

Nochmal die Homepage ,


http://www.tripos.com/

heute wenn alles gut geht auf die 30 $ .


pp

[papermaker]

Leider ist der Kurs durch den Verkauf der fast 900.000 Stck., von LION , weiter zurückgegangen .
Jetzt bei 27 $ , aber das ändert an der Qualität von
Tripos nichts .

pp

[papermaker]

http://quotes.freerealtime.com/dl/frt/N?symbol=TRPS&art=C200…

Schlußkurs 22,22 $ ,geht es morgen noch tiefer , ich
weiß es nicht .


pp

[Bostein]

Lange sehen wir solch tiefe Kurse bestimmt nicht mehr.
Der Wert ist doch top, da stimmt wirlich alles und Umsätze
scheine ja weiter hoch zu bleiben. Vieleicht ein Kräftemessen zwischen Kleinanlegern und Fonds.

[papermaker]

http://www.nasdaq.com/asp/quotes_news.asp?symbol=TRPS%60&sel…


pp

[papermaker]

noch mal ,

http://quotes.freerealtime.com/dl/frt/N?symbol=TRPS&art=C200…


pp

[papermaker]

@all ,


Kurs 19,65 $ , erstens kommt es anders , und zweitens als man denkt .

Ob das nun schon Einstiegskurse sind , weiß ich auch nicht .


pp

[Kelbi]

Heute + 19 % nicht schlecht oder?

Könnte an den Unternehmensmeldungen liegen, TRPS hat u.a. auch verkündet in allen Quartalen profitabel zu arbeiten. Der Gewinn soll im ersten Halbjahr auf Vorjahresniveau bleiben und im zweiten Ha´lbjahr dann wohl steigen.

Nach der jüngsten Gewinnwarnung hatten die Anleger wohl mit schlimmeren gerechnet, scheint mir. Mal sehen wie es weitergeht.

Gute Nacht:-)

[Kelbi]

Tripos Expects Second-Quarter Loss on Revenue Shortfall

By Michael Dunn
Staff Reporter
07/01/2002 08:12 AM EDT


Drug research and consulting firm Tripos (TRPS:Nasdaq - news - commentary - research - analysis) warned on Monday that it would post a second-quarter loss amid delayed customer orders and general uncertainty in the pharmaceutical industry.

Excluding charges, the company now expects to lose $1.8 million to $2.1 million, or 20 cents to 25 cents a share, in the quarter, well below the Thomson Financial/First Call consensus estimate of a profit of 7 cents a share.


Revenue is expected to be between $10.5 million and $11 million, with lower revenue in the Discovery Software licensing and Software Consulting Services divisions. The company said the shortfall was caused by delayed purchase decisions from customers of both lines.

In a press release, Tripos said, "We have experienced delayed decision-making among our customers on a series of opportunities that were anticipated at the end of the second quarter. The general uncertainty in the pharmaceutical and biotechnology industries impeded the closing of pending contracts."

Going forward, the company sees full-year revenue at $53 million to $58 million, missing the consensus estimate of $67.1 million.

Shares of Tripos were recently plunging about 24% to $16.50 in premarket trading on the news after closing at $21.80 Friday.

Tja nun hats auch Tripos erwischt: aktuell -62 % auf knapp über 8 USD.....